Sernova is developing regenerative medicine therapeutics based on a novel implantable device creating an organ-like environment and therapeutic cells to provide a functional cure for chronic diseases. Sernova’s approach showed success in preclinical studies in three disease indications and presented initial data from its ongoing diabetes clinical trial demonstrating transplanted therapeutic cell survival within the device, insulin production in the bloodstream and important efficacy indicators, such as improved HbA1c and reduction in insulin use and hypoglycemic unawareness events.

Sernova logo



Event details

Date: October 5 - 9, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


24 in total